Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 730734, 8 pages
http://dx.doi.org/10.1155/2013/730734
Research Article

Opposite Effects of Single-Dose and Multidose Administration of the Ethanol Extract of Danshen on CYP3A in Healthy Volunteers

1Lab of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2Lab of Pharmacokinetics, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
3Key Lab of Drug Metabolism & Pharmacokinetics, China Pharmaceutics University, Nanjing 210038, China

Received 10 April 2013; Revised 13 July 2013; Accepted 27 August 2013

Academic Editor: Moses S. S. Chow

Copyright © 2013 Furong Qiu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. O. Cheng, “Danshen: a popular chinese cardiac herbal drug,” Journal of the American College of Cardiology, vol. 47, no. 7, pp. 1498–1499, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. T. O. Cheng, “Cardiovascular effects of Danshen,” International Journal of Cardiology, vol. 121, no. 1, pp. 9–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. H. Lee, Y.-J. Shin, H. J. Kim, J.-H. Oh, Y. P. Jang, and Y.-J. Lee, “Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions,” International Journal of Pharmaceutics, vol. 410, no. 1-2, pp. 68–74, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Y. Xu, R. Z. Wan, Y. P. Lin, L. Yang, Y. Chen, and C. X. Liu, “Recent advance on reseach and application of Salvia miltiorrhiza,” Asian Journal of Drug Metabolism and Pharmacokinetics, vol. 7, pp. 99–130, 2007. View at Google Scholar
  5. W. Zhou and T. J. C. Ruigrok, “Protective effect of Danshen during myocardial ischemia and reperfusion: an isolated rat heart study,” American Journal of Chinese Medicine, vol. 18, no. 1-2, pp. 19–24, 1990. View at Google Scholar · View at Scopus
  6. X.-Y. Ji, B. K.-H. Tan, and Y.-Z. Zhu, “Salvia miltiorrhiza and ischemic diseases,” Acta Pharmacologica Sinica, vol. 21, no. 12, pp. 1089–1094, 2000. View at Google Scholar · View at Scopus
  7. Y.-H. Kuo, Y.-L. Lin, M.-J. Don, R.-M. Chen, and Y.-F. Ueng, “Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza,” Journal of Pharmacy and Pharmacology, vol. 58, no. 4, pp. 521–527, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Yu, S. Ye, H. Sun et al., “PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA,” Chemico-Biological Interactions, vol. 177, no. 1, pp. 58–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Wang, C. M. Cheung, W. Y. W. Lee, P. M. Y. Or, and J. H. K. Yeung, “Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro,” Phytomedicine, vol. 17, no. 11, pp. 868–875, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. T. D. Bjornsson, J. T. Callaghan, H. J. Einolf et al., “The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective,” Journal of Clinical Pharmacology, vol. 43, no. 5, pp. 443–469, 2003. View at Google Scholar · View at Scopus
  11. H. Hao, G. Wang, N. Cui, J. Li, L. Xie, and Z. Ding, “Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion,” Planta Medica, vol. 72, no. 14, pp. 1311–1317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Hao, G. Wang, P. Li, J. Li, and Z. Ding, “Simultaneous quantification of cryptotanshinone and its active metabolite tanshinone IIA in plasma by liquid chromatography/tandem mass spectrometry (LC-MS/MS),” Journal of Pharmaceutical and Biomedical Analysis, vol. 40, no. 2, pp. 382–388, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Zhou, M. Chow, and Z. Zuo, “Improved quality control method for Danshen products—consideration of both hydrophilic and lipophilic active components,” Journal of Pharmaceutical and Biomedical Analysis, vol. 41, no. 3, pp. 744–750, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Qiu, R. Zhang, J. Sun et al., “Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes,” Drug Metabolism and Disposition, vol. 36, no. 7, pp. 1308–1314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Garrett, J. Smeraglia, X. Lin, L. Tan, and J. Tran, “A pilot study to assess simultaneous administration of oral midazolam (MDZ) and fexofenadine (FEX) for the evaluation of cytochrome (CYP) 3A4 and P-glycoprotein (P-gp) activities,” Clinical Pharmacology & Therapeutics, vol. 77, p. 45, 2005. View at Google Scholar
  16. K.-A. Seo, S. K. Bae, Y.-K. Choi, C. S. Choi, K.-H. Liu, and J.-G. Shin, “Metabolism of 1′- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7,” Drug Metabolism and Disposition, vol. 38, no. 11, pp. 2007–2013, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C.-Y. Wu and L. Z. Benet, “Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system,” Pharmaceutical Research, vol. 22, no. 1, pp. 11–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. C. Gorski, D. R. Jones, B. D. Haehner-Daniels, M. A. Hamman, E. M. O'Mara Jr., and S. D. Hall, “The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin,” Clinical Pharmacology and Therapeutics, vol. 64, no. 2, pp. 133–143, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Sakuda, T. Akabane, and T. Teramura, “Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans,” Xenobiotica, vol. 36, no. 4, pp. 331–340, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Qiu, R. Zhang, G. Wang et al., “Activation of CYP3A-mediated testosterone 6β-hydroxylation by tanshinone IIA and midazolam 1-hydroxylation by cryptotanshinone in human liver microsomes,” Xenobiotica, vol. 40, no. 12, pp. 800–806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. O. A. Fahmi, M. Kish, S. Boldt, and R. S. Obach, “Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes,” Drug Metabolism and Disposition, vol. 38, no. 9, pp. 1605–1611, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Qiu, G. Wang, R. Zhang, J. Sun, J. Jiang, and Y. Ma, “Effect of danshen extract on the activity of CYP3A4 in healthy volunteers,” British Journal of Clinical Pharmacology, vol. 69, no. 6, pp. 656–662, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. H. G. Xie and R. B. Kim, “St. John’s wort-associated drug interaction: short-term inhibition and long-term induction,” Clinical Pharmacology & Therapeutics, vol. 73, pp. 41–50, 2005. View at Google Scholar
  24. L. B. Moore, D. J. Parks, S. A. Jones et al., “Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands,” Journal of Biological Chemistry, vol. 275, no. 20, pp. 15122–15127, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. W. El-Sankary, N. J. Plant, G. G. Gibson, and D. J. Moore, “Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors,” Drug Metabolism and Disposition, vol. 28, no. 5, pp. 493–496, 2000. View at Google Scholar · View at Scopus
  26. J.-M. Pascussi, L. Drocourt, S. Gerbal-Chaloin, J.-M. Fabre, P. Maurel, and M.-J. Vilarem, “Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor,” European Journal of Biochemistry, vol. 268, no. 24, pp. 6346–6357, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Geick, M. Eichelbaum, and O. Burk, “Nuclear receptor response elements mediate induction of intestinal MDR1 by Rifampin,” Journal of Biological Chemistry, vol. 276, no. 18, pp. 14581–14587, 2001. View at Publisher · View at Google Scholar · View at Scopus